Phase 2Active, not recruiting

A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults

A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Adults Age ≥65 Years

Sponsor
Restorbio Inc. (Industry)
Enrollment
60 planned
Conditions
Covid19
Interventions
RTB101; Placebo
Ages
older adults
Registry
NCT04584710

Full record on ClinicalTrials.gov

From the registry

The proposed trial will obtain preliminary data on the feasibility of studying RTB101 as compared to placebo for COVID-19 post-exposure prophylaxis in adults age ≥ 65 years to inform the design of a subsequent pivotal trial.

Primary outcomes

  • To determine the length of time from date of receipt of a positive SARS-CoV2 test result to date of first dose of study drug in asymptomatic adults age ≥ 65 years

History

  1. Primary completion

  2. Last registry update

  3. Registered

  4. Started